FC
ABUS icon

Foursixthree Capital’s Arbutus Biopharma ABUS Stock Holding History

Foursixthree Capital’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-1,978,975
Closed -$8.98M – 18
2025
Q3 		$8.98M Sell
1,978,975
-578,392
-23% -$2.12M 2.47% 12
2025
Q2 		$7.9M Buy
2,557,367
+106,946
+4% +$355K 2.76% 9
2025
Q1 		$8.55M Buy
+2,450,421
New +$8.17M 2.36% 11

Other funds holding ABUS

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
WCM
Whitefort Capital Management New York $406M AUM 84.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Foursixthree Capital's ABUS Position: Q4 2025 in Review

Foursixthree Capital sold out of Arbutus Biopharma (ABUS) in Q4 2025, closing a stake of 1,978,975 shares — an estimated $8.98M sold.

Foursixthree Capital first reported a position in ABUS in Q1 2025 and held it in 3 quarters. The position peaked at $8.98M in Q3 2025. 172 funds tracked by Wall St. Rank hold ABUS as of Q4 2025.

  • Foursixthree Capital reported no remaining Arbutus Biopharma position as of Q4 2025 after selling out during the quarter.
  • Foursixthree Capital sold 1,978,975 Arbutus Biopharma shares in Q4 2025, an estimated $8.98M.
  • Foursixthree Capital first reported a position in Arbutus Biopharma in Q1 2025 and held it in 3 quarters.
  • Foursixthree Capital's Arbutus Biopharma position peaked at $8.98M in Q3 2025.
  • 172 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q4 2025.

Based on Foursixthree Capital's 13F filing for Q4 2025, filed 17 Feb 2026.